Therapeutic Salts: The Carrier Chemistry Beneath the Opticeutical Category

Pharmaceutical chemistry has used salt formation as a formulation tool for the better part of a century. The conversion of an active compound to its salt form modulates solubility, stability, and dissolution behaviour in ways that the free-acid or free-base form does not provide. The discipline is well established. Most pharmaceutical small molecules in commercial use today are formulated as one or another salt rather than as the parent compound.

When the active compound is a short-chain regulatory peptide rather than a small molecule, the salt-formation discipline has to be re-derived. The chemistry of peptide stabilisation does not map cleanly onto the salt-formation playbook developed for the small-molecule pharmacopoeia. The pH-sensitivity of peptide bonds, the conformational requirements of short sequences, and the bioavailability constraints of routes of administration relevant to consumer products — sublingual, transdermal, oral — together produce a set of formulation problems that conventional pharmaceutical salts do not always solve.

What the formulation problem looks like in detail

Short-chain peptides in their free form are moisture-sensitive. They aggregate, hydrolyse, and lose conformational integrity during the storage and handling cycle that a consumer product is subject to. They are pH-sensitive. The pH of the gastric environment, the pH gradients across mucosal surfaces, and the pH of common excipient matrices all interact with the peptide in ways that can degrade the active or alter its delivery profile. They are enzymatically labile. Peptidases distributed throughout the gut, the mucosal surfaces, and the systemic circulation cleave short peptides at rates that, without carrier protection, make consistent dose-to-target-tissue delivery unreliable.

These three constraints, taken together, define the formulation envelope inside which the carrier chemistry must work. The carrier must stabilise the peptide during storage and through the relevant delivery route. It must release the peptide in a conformation and at a rate that allows the target tissue to take up the compound. And it must do so within the regulatory envelope of either a dietary supplement or, in some clinical applications, a compounded preparation — meaning that the carrier itself cannot introduce a novel excipient class requiring de novo regulatory characterisation.

Why conventional pharmaceutical excipients are not enough

The conventional pharmaceutical excipient toolkit was developed primarily for small-molecule drug formulation. It provides cellulose-based binders, lactose-based diluents, magnesium-stearate-class lubricants, and a range of stabilisers and preservatives that work well for the chemistry the toolkit was developed against. None of this is wrong. It is well-characterised, broadly safe at typical use levels, and supported by extensive regulatory precedent.

It is also, for peptide-class formulation, often insufficient. The stabilisation requirements that short-chain peptides have are different in kind from the stabilisation requirements that conventional small molecules have. The bioavailability assumptions baked into standard excipient choices were derived from small-molecule pharmacology and do not transfer cleanly to peptide chemistry. Asking the conventional excipient toolkit to handle peptide formulation is asking it to solve a problem it was not designed to solve.

“The conventional excipient toolkit is not wrong. It is well-characterised. It is also not sufficient for peptide-class formulation. Asking it to handle that chemistry is asking it to solve a problem it was not designed to solve.”

The Opti-Salt™ carrier family

Opti-Salt™ is the institutional name for a family of therapeutic salt carrier formulations developed specifically for short-chain peptide delivery in the Opticeutical category. The development goal was a carrier chemistry that addresses the three formulation constraints described above — moisture sensitivity, pH sensitivity, enzymatic lability — without introducing novel excipients that would require de novo regulatory characterisation, and without compromising the bioavailability profile required for the routes of administration the delivery platform portfolio supports.

The specific salt chemistries within the Opti-Salt™ family are not publicly disclosed while patent prosecution continues. The publicly stateable shape of the family is as follows. Multiple distinct salt forms suited to multiple distinct routes of administration. Stabilisation behaviour validated across the storage and handling cycle that consumer products require. Dissolution and release profiles matched to the route of administration in each application. Excipient compatibility with the broader formulation context in which the carrier is used, including compatibility with the existing pharmaceutical excipient toolkit where that toolkit is appropriate.

Where the carrier sits relative to the active

A finished Opticeutical-qualified product, in the formulation architecture the category supports, combines three layers. The active is a specific peptide-class compound, either trade-named under the Atumnus IP portfolio or licensed from an adjacent source where compatible with the standard. The carrier is a specific Opti-Salt™ formulation matched to the active and the delivery route. The delivery platform is a specific route-of-administration architecture matched to the consumer product format.

Each of the three layers is independently developed, independently characterised, and independently subject to qualification under the Opticeutical Standard. A peptide-class active in a generic capsule with a generic excipient matrix does not qualify, even if the active itself is well-formulated, because the formulation context does not support the active's chemistry. A well-formulated carrier-and-platform combination with the wrong active does not qualify, because the mechanism rationale does not match the claim. All three layers have to work together, and the qualification process verifies that they do.

What this means for partners working in the formulation space

Contract formulators, manufacturing partners, and brand owners interested in developing Opticeutical-qualified products operate under license to the relevant Opti-Salt™ chemistries when their product requires carrier support that the conventional excipient toolkit cannot provide. The license is product-specific. The licensed carrier formulation is provided with the technical documentation required for the formulation work, and Atumnus technical support is available during the qualification phase to address formulation-specific questions that the documentation does not cover.

For partners whose existing formulation discipline is strong enough to handle the carrier chemistry directly under their own development cycle, the licensing relationship still applies — the carrier is IP — but the technical-support engagement is lighter. The specific posture is negotiated per partnership. Inquiries from formulators and contract manufacturers regarding the carrier system are routed through the partnerships channel.